---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004750"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:46:55.070085+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroPace reports Q4 2022 preliminary revenue $12.8M (+16% YoY); appoints Dr. Uri Geiger to board

## Summary
- Q4 2022 total revenue expected ~$12.8M, up 16% from $11.0M in Q4 2021; initial implant revenue $9.8M (+15%).
- Full-year 2022 revenue expected ~$45.5M, flat vs $45.2M in 2021; initial implant revenue $35.7M (+6%).
- Dr. Uri Geiger, founder of Accelmed Partners, appointed to Board effective Jan 5, 2023; granted option for 120,521 shares at $1.535.
- Replacement implant revenue declined 44% in Q4 ($1.4M) and 29% for FY2022 ($8.2M); DIXI Medical contributed $1.6M.

## SEC filing metadata
- accession: 0001193125-23-004750
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/d407794d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004750
- JSON: https://secwatch.observer/filing/0001193125-23-004750.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004750.txt

## Key facts
- Earnings Releases
  NeuroPace Inc reported fiscal quarter and year ended December 31, 2022 results: revenue approximately $12.8 million.
  - Period: fiscal quarter and year ended December 31, 2022
  - Revenue: approximately $12.8 million
  - Result: preliminary results
  source text: December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors. Preliminary Unaudited Fourth Quarter 2022 • Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021. • Initial implant revenue is expected to be approximately $9.8 million, representing growth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm
- Executive change
  Dr. Uri Geiger was appointed as Director at NeuroPace Inc.
  - Action: appointed
  - Role: Director
  source text: On January 4, 2023, the NeuroPace Board appointed Dr. Uri Geiger as a Class III director, effective as of January 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.